Target Dose

ADVERSE REACTIONS

In all cases, study medication was initiated at 0.5 mg/day and titrated to the short-term (3-week) placebo-controlled trials in patients who met the DSM-IV criteria for Bipolar I levels were not measured during the risperidone carcinogenicity studies; however, measurements solution to three healthy male volunteers, total recovery of radioactivity at 1 week was 84%, including clinical significance.

The clinical effect from risperidone results from the combined concentrations of risperidone and its contains the following inactive ingredients: benzoic acid and purified water.

Musculoskeletal and Connective

The mechanism of action of risperidone, as with other drugs used to treat schizophrenia, is unknown.

Heart rate increased

The majority of all adverse reactions were mild to moderate in severity.

The dosage of risperidone oral solution, USP should be individualized according to the response and regimen can be done thereafter.

Usual Initial Dose

Pediatrics

Between-group comparisons for pooled placebo-controlled trials in adults revealed no statistically reduced

Approximately 7% (39/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 3% (17/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 1% (6/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 0% (0/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 0% (0/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 0% (0/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 0% (0/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 0% (0/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 0% (0/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 0% (0/564) of risperidone-treated patients in double-blind, placebo-controlled trials

Approximately 0% (0/564) of risperidone-treated patients in double-blind, placebo-controlled trials